Results 101 to 110 of about 727,997 (259)

Extending UTAUT with national identity and fairness to understand user adoption of DCEP in China. [PDF]

Sci Rep, 2022
Wu B, An X, Wang C, Shin HY.
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen, Jiancheng Cheng, Ruili Hou, Xiaoyuan Zheng, Li Su, Maria Moksnes Bjaanæs, Anna Karlsson, Maria Planck, Johan Staaf, Åslaug Helland, Manel Esteller, David C. Christiani, Feng Chen, Xiaofei Cao, Ruyang Zhang   +14 more
wiley   +1 more source

THEATRE HISTORIOGRAPHY AND NATIONAL IDENTITY

Fluminensia: Journal for Philological Research, 2014
The paper discusses the relationship between the (Croatian) theatre historiography and the (Croatian) national identity, a topic rarely considered in Croatian theatre studies.
Martina Petranović
doaj  

Assessing young children's national identity through human-computer interaction: A game-based assessment task. [PDF]

Front Psychol, 2022
Hong X, Liu Q.
europepmc   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

National identity predicts public health support during a global pandemic. [PDF]

Nat Commun, 2022
Van Bavel JJ, Cichocka A, Capraro V, Sjåstad H, Nezlek JB, Pavlović T, Alfano M, Gelfand MJ, Azevedo F, Birtel MD, Cislak A, Lockwood PL, Ross RM, Abts K, Agadullina E, Aruta JJB, Besharati SN, Bor A, Choma BL, Crabtree CD, Cunningham WA, De K, Ejaz W, Elbaek CT, Findor A, Flichtentrei D, Franc R, Gjoneska B, Gruber J, Gualda E, Horiuchi Y, Huynh TLD, Ibanez A, Imran MA, Israelashvili J, Jasko K, Kantorowicz J, Kantorowicz-Reznichenko E, Krouwel A, Laakasuo M, Lamm C, Leygue C, Lin MJ, Mansoor MS, Marie A, Mayiwar L, Mazepus H, McHugh C, Minda JP, Mitkidis P, Olsson A, Otterbring T, Packer DJ, Perry A, Petersen MB, Puthillam A, Riaño-Moreno JC, Rothmund T, Santamaría-García H, Schmid PC, Stoyanov D, Tewari S, Todosijević B, Tsakiris M, Tung HH, Umbreș RG, Vanags E, Vlasceanu M, Vonasch A, Yucel M, Zhang Y, Abad M, Adler E, Akrawi N, Mdarhri HA, Amara H, Amodio DM, Antazo BG, Apps M, Ay FC, Ba MH, Barbosa S, Bastian B, Berg A, Bernal-Zárate MP, Bernstein M, Białek M, Bilancini E, Bogatyreva N, Boncinelli L, Booth JE, Borau S, Buchel O, Cameron CD, Carvalho CF, Celadin T, Cerami C, Chalise HN, Cheng X, Cian L, Cockcroft K, Conway J, Córdoba-Delgado MA, Crespi C, Crouzevialle M, Cutler J, Cypryańska M, Dabrowska J, Daniels MA, Davis VH, Dayley PN, Delouvee S, Denkovski O, Dezecache G, Dhaliwal NA, Diato AB, Di Paolo R, Drosinou M, Dulleck U, Ekmanis J, Ertan AS, Etienne TW, Farhana HH, Farkhari F, Farmer H, Fenwick A, Fidanovski K, Flew T, Fraser S, Frempong RB, Fugelsang JA, Gale J, Garcia-Navarro EB, Garladinne P, Ghajjou O, Gkinopoulos T, Gray K, Griffin SM, Gronfeldt B, Gümren M, Gurung RL, Halperin E, Harris E, Herzon V, Hruška M, Huang G, Hudecek MFC, Isler O, Jangard S, Jørgensen FJ, Kachanoff F, Kahn J, Dangol AK, Keudel O, Koppel L, Koverola M, Kubin E, Kunnari A, Kutiyski Y, Laguna O, Leota J, Lermer E, Levy J, Levy N, Li C, Long EU, Longoni C, Maglić M, McCashin D, Metcalf AL, Mikloušić I, El Mimouni S, Miura A, Molina-Paredes J, Monroy-Fonseca C, Morales-Marente E, Moreau D, Muda R, Myer A, Nash K, Nesh-Nash T, Nitschke JP, Nurse MS, Ohtsubo Y, Oldemburgo de Mello V, O'Madagain C, Onderco M, Palacios-Galvez MS, Palomäki J, Pan Y, Papp Z, Pärnamets P, Paruzel-Czachura M, Pavlović Z, Payán-Gómez C, Perander S, Pitman MM, Prasad R, Pyrkosz-Pacyna J, Rathje S, Raza A, Rêgo GG, Rhee K, Robertson CE, Rodríguez-Pascual I, Saikkonen T, Salvador-Ginez O, Sampaio WM, Santi GC, Santiago-Tovar N, Savage D, Scheffer JA, Schönegger P, Schultner DT, Schutte EM, Scott A, Sharma M, Sharma P, Skali A, Stadelmann D, Stafford CA, Stanojević D, Stefaniak A, Sternisko A, Stoica A, Stoyanova KK, Strickland B, Sundvall J, Thomas JP, Tinghög G, Torgler B, Traast IJ, Tucciarelli R, Tyrala M, Ungson ND, Uysal MS, Van Lange PAM, van Prooijen JW, van Rooy D, Västfjäll D, Verkoeijen P, Vieira JB, von Sikorski C, Walker AC, Watermeyer J, Wetter E, Whillans A, Willardt R, Wohl MJA, Wójcik AD, Wu K, Yamada Y, Yilmaz O, Yogeeswaran K, Ziemer CT, Zwaan RA, Boggio PS.   +256 more
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Swedish exceptionalism and the Sars-CoV2 pandemic crisis: Representations of crisis and national identity in the public sphere. [PDF]

Risk Hazards Crisis Public Policy, 2022
Simonsen S.
europepmc   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source